Healthcare & Life Sciences

Public and private health actors must find the most appropriate organizational structures, management methods, and financing to ensure the maximum enjoyment of the right to health, by efficiently using available resources, maintaining essential service levels throughout the country, promoting technological innovation, pharmaceutical research, and modernizing health infrastructure. This is the only way to respond effectively to regional needs and adapt them to the safety and efficiency standards required in the current context.

By tapping into our professionals’ deep knowledge, the various stakeholders in the healthcare sector can create public and private value and increase the competitiveness and efficiency of each operator, receiving support in commercial transactions, approval and licensing procedures, risk management, and litigation before administrative tribunals and courts.

We provide healthcare and social service providers, pharmaceutical and biotech companies, and medical device manufacturers with the highest level of support in their dealings with public and regulatory authorities, as well as in strategic growth, financial, market, and performance optimization.

In addition to our specific expertise in the health and pharmaceutical sectors, we have in-depth knowledge of the dynamics of procuring works, services, and supplies, and of PPP transactions for financing, constructing, and managing hospital facilities and regional facilities. We also have solid expertise in the energy sector, implementing efficiency improvements in existing and newly built facilities; and consolidated experience in public procurement and competition law, as well as in healthcare advertising, telemedicine, and digital technologies.

Our professionals have been involved in numerous accreditation and licensing processes for public and private healthcare facilities, and in creating or transforming existing facilities; in the pharmaceutical sector, they have helped major players obtain licenses, contracts for the supply of drugs and biomedical devices, and in relations with the regulatory authorities, including drug-pricing issues.